Taussig Cancer Institute, Cleveland Clinic Foundation
Dr. Shilpa Gupta is the Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic.
Dr. Gupta obtained her Medical Degree at the Lady Hardinge Medical College in New Delhi, India and completed a residency in Internal Medicine at the University of Connecticut Health Center. She completed Hematology-Oncology fellowship at Georgetown University and Thomas Jefferson University followed by a Genitourinary Oncology Translational Research fellowship at Thomas Jefferson University. Dr. Gupta was a faculty at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in Genitourinary Oncology and Experimental Therapeutics from 2011 until 2015. From 2015 until 2019, she was Lead for the Solid Tumor Phase 1 Program at Masonic Cancer Center, University of Minnesota. Dr. Gupta serves on the ASCO Annual Scientific Committee, SITC Cancer Immunotherapy Guidelines, International Bladder Cancer Group core committee and SIU Innovators. She also serves on the Steering Committee and Scientific Advisory Board for the BCAN.
Dr. Gupta’s research interests are novel drug development and biomarkers of response and resistance to therapies in bladder cancer. Dr. Gupta has led several Investigator Initiated Trials in Genitourinary Cancers and has leadership roles in several NCI trials.
Dr. Gupta is active in several professional organizations including the American Society of Clinical Oncology (ASCO), American Urologic Association (AUA), American Association of Cancer Research (AACR), Society of Urologic Oncology (SUO), Society of Immunotherapy for cancer (SITC), Prostate Cancer Foundation (PCF) and the European Society of Medical Oncology (ESMO).
AbbVie Janssen Pfizer Takeda (Individual(s) Involved: Self): Consultant; AstraZeneca (Individual(s) Involved: Self): Consultant; BMS (Individual(s) Involved: Self): Consultant, Speaker's Bureau; Consulting (to institution): Ipsen, Array Biopharma, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte and Merck. (Individual(s) Involved: Self): Speaker's Bureau; EMD Serona (Individual(s) Involved: Self): Consultant; Janssen (Individual(s) Involved: Self): Speaker's Bureau; Loxo Oncology (Individual(s) Involved: Self): Consultant; Merck (Individual(s) Involved: Self): Consultant; Natera (Individual(s) Involved: Self): Consultant
Wednesday, March 9, 2022
12:50 PM – 3:20 PM
Wednesday, March 9, 2022
2:29 PM – 2:35 PM
Wednesday, March 9, 2022
2:35 PM – 3:20 PM
Wednesday, March 9, 2022
3:30 PM – 4:25 PM
Wednesday, March 9, 2022
3:35 PM – 4:25 PM
Wednesday, September 28, 2022
1:10 PM – 3:05 PM
Wednesday, September 28, 2022
1:42 PM – 1:49 PM
Wednesday, September 28, 2022
2:40 PM – 3:05 PM